massive headache with migraine; diarrhea; 36 hours after 2nd vaccine dose, respiratory asthma like event with heaviness/pain in chest and lung/productive cough with wheezing; 36 hours after 2nd vaccine dose, respiratory asthma like event with heaviness/pain in chest and lung/productive cough with wheezing; 36 hours after 2nd vaccine dose, respiratory asthma like event with heaviness/pain in chest and lung/productive cough with wheezing; 36 hours after 2nd vaccine dose, respiratory asthma like event with heaviness/pain in chest and lung/productive cough with wheezing; 36 hours after 2nd vaccine dose, respiratory asthma like event with heaviness/pain in chest and lung/productive cough with wheezing; 36 hours after 2nd vaccine dose, respiratory asthma like event with heaviness/pain in chest and lung/productive cough with wheezing; 36 hours after 2nd vaccine dose, respiratory asthma like event with heaviness/pain in chest and lung/productive cough with wheezing; nauseous; dizzy; headache; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 14Apr2021 at 11:15 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included allergic asthma from cat dander and allergy to sulfa antibiotics. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration on 24Mar2021 at 11:15 (at the age of 46-years-old) as a single dose for COVID-19 immunisation and received metoclopramide (REGLAN), hydrocodone bitartrate/paracetamol (NORCO) and trazodone (MANUFACTURER UNKNOWN); all on unknown date for unknown indication and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 11:25, within 10 minutes, the patient experienced nauseous, dizzy and headache and had same impact for 24 hours. On 15Apr2021 at 23:15, 36 hours after 2nd vaccine dose, the patient experienced respiratory asthma like event with heaviness/pain in chest and lung/productive cough with wheezing. On 18Apr2021, 4 days later, the patient experienced massive headache with migraine all day (24 hour long) and diarrhea for four hours. On 19Apr2021, the patient felt fine again. The patient did not receive any treatment for the nauseous, dizzy, headache, massive headache with migraine and diarrhea, Therapeutic measures were taken as a result of respiratory asthma like event with heaviness/pain in chest and lung/productive cough with wheezing and included treatment herself with emergency inhaler (unspecified). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nauseous, dizzy, headache, respiratory asthma like event with heaviness/pain in chest and lung/productive cough with wheezing and massive headache with migraine was recovered on unknown date in Apr2021 and of the event diarrhea was recovered on 18Apr2021, after the duration of 4 hours.   No follow-up attempts are needed. No further information is expected.